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Abnormal pulmonary vascular response to exercise can be a marker of early pulmonary arterial 
hypertension (PAH). We have previously demonstrated that the pressure-flow relationship of 
mean pulmonary artery pressure (mPAP) to cardiac output (CO) measurement could be applied 
to predict future development of overt PH in at-risk patients (e.g. scleroderma:SS) (1). The 
ΔmPAP/ΔCO can complement our understanding of early pulmonary vascular disease in at-risk 
patients, and help define abnormal pulmonary vascular response to exercise as an impaired 
pulmonary vascular capacity. 
We sought to assess clinical worsening during long-term follow-up in at-risk patients and 
to evaluate whether vasodilator therapy improved pulmonary vascular response, exercise 
capacity and prognosis in exercise induced pulmonary hypertension (EIPH). 
We designed a prospective, single-center, open-label, uncontrolled treatment trial of 
EIPH with PAH specific therapies in SS or mixed connective tissue disease (MCTD) with SS 
features. We prospectively performed 6 minute-walk (6MW) stress echocardiographic (SE) 
studies in 243 SS or MCTD patients with scleroderma features (1). For 6MW SE, we used an 
impedance-based device to measure CO, which was combined with tricuspid regurgitation-based 
right ventricular pressure, from which mPAP was estimated. Patients with non-EIPH based on 
our previous work (ΔmPAP/ΔCO≤3.3 and/or exercise mPAP≤25mmHg) were assigned only to 
the initial observational study. All patients with EIPH (ΔmPAP/ΔCO>3.3 and exercise 
mPAP>25 mmHg) received explanations for the exercise right heart catheter. We obtained 
informed consent for exercise RHC in 29 patients with EIPH. 
 At right heart catheter (RHC), EIPH was defined as mPAP at peak ≥30mmHg and 
pulmonary artery wedge pressure at peak <25mmHg during supine bicycle ergometer. After 




administration of PAH specific therapies (non-treatment and treatment groups). The composite 
outcome was time to clinical worsening. The efficacy end point was change in ΔmPAP/ΔCO and 
6MW distance (6MWD) from baseline to one year. 
The study population consisted of 243 patients. No EIPH was observed in 186 of 243 
patients, and EIPH was observed in 57 of 243 patients in this cohort (Table 1). 
During a median period of 4.3 years, 56 patients (23%) reached the composite outcome 
(death, n=3; unplanned hospitalization for worsening of PAH, n=12; worsening of World Health 
Organization functional class by at least one level and ≥15% decrease from baseline in 6MWD 
with increased PAP: n=41). Patients with EIPH had significantly shorter event-free survival than 
with non-EIPH. EIPH (HR,1.95; 95%CI [1.10–3.45]; p=0.023) was associated with time-to-
event, independent of age, sex, and E/e’. 
In patients with exercise RHC, 28 of 29 patients fulfilled the catheter criteria of EIPH. In 
our cohort, 14 of 29 patients received PAH specific therapies (treatment group) and 15 of 29 
patients did not receive these therapies (control group) based on patient preference. There was no 
difference between control and treatment groups except for CO at rest. 
6MWD was similar in patients with control and treatment groups at the beginning of the 
follow-up (p=0.69). At 1-year follow-up, treatment group had a trend of longer 6MWD than 
control group (p=0.09). ΔmPAP/ΔCO was also similar in patients with control and treatment 
groups at the beginning of the follow-up (p=0.30). At 1-year follow-up, treatment group had 
lower ΔmPAP/ΔCO than control group (p=0.02). 
In RHC cases, 10 patients reached the composite outcome with only 1 died patient. The 
composite outcome occurred in 8% of the patients in the treatment group as compared with 36% 




We demonstrated that 57 of 243 patients at risk for PAH (due to SS or MCTD with SS 
features) with normal resting echocardiographic findings had EIPH based on an elevated 
ΔmPAP/ΔCO obtained by 6MW SE. Patients with EIPH had significantly shorter event-free 
survival than patients with non-EIPH. We note significant improvements in a number of post-
treatment ΔmPAP/ΔCO patients compared to control values. Patients with EIPH who received 
treatment had longer event-free survival than who did not. 
Patients with treatment received several pulmonary vasodilators. Based upon attending 
physician preference, the majority of our patients were treated with endothelin receptor 
antagonists (71%), which is similar to prior publications that primarily utilized ambrisentan 
therapy. Our results show that pulmonary vasodilators can improve exercise hemodynamics in 
general. We found that ΔmPAP/ΔCO improved significantly. These changes are results of lower 
vascular resistance after treatment. Intervention in early pulmonary vascular disease may 
improve endothelial function and subsequent distal vasculopathy. 
In conclusion, patients with EIPH had significantly shorter event-free survival than 
patients with non-EIPH. This is the first study to demonstrate that early intervention in patients 
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Table 1: Clinical data in entire cohort 
Entire cohort Non-EIPH EIPH p value 
Number 186 57 
Age 57±13 62±12 0.003 
Male, % 22 (12) 5 (9) 0.65 
Body mass index 22±3 22±3 0.73 
WHO Class I/II/III/IV 41/112/33/0 10/35/12/0 0.41 
History 
SS, % 150 (81) 47 (82) 0.76 
 MCTD with SS features, % 36 (19) 10 (18) 0.76 
Respiratory function 
%EFV1, % 80±20 85±15 0.42 
%FVC, % 107±26 105±19 0.79 
%DLCO 76±20 73±22 0.69 
Baseline hemodynamics 
HR, bpm 69±11 69±11 0.93 
Systolic BP, mmHg 122±19 126±21 0.19 
Diastolic BP, mmHg 70±11 72±12 0.47 
SpO2, % 98±1 97±2 0.09 
Post 6-min walk hemodynamics 
HR, bpm 91±17 91±17 0.93 
Systolic BP, mmHg 126±23 133±28 0.14 
Diastolic BP, mmHg 69±11 73±18 0.07 
SpO2, % 97±2 94±4 0.002 
6MW distance, meter 446±95 439±85 0.59 
Echocardiographic variables 
LVEDVi, ml/m2 49±10 48±13 0.44 
LVESVi, ml/m2 17±4 19±5 0.24 
LVEF, % 65±3 66±3 0.19 
LAVi, ml/m2 26±7 29±11 0.07 
E/e' 7±2 8±4 0.02 
RVEDA, cm2 14±3 13±3 0.25 
RVESA, cm2 8±2 8±2 0.63 
RVFAC, % 42±12 41±11 0.36 
TAPSE, mm 22±4 22±4 0.63 
Baseline echocardiographic hemodynamics 
TR-PG, mmHg 20±4 24±5 <0.001 
  Mean PAP, mmHg 17±3 19±3 <0.001 
  CO, l/min 4.0±1.1 3.7±1.3 0.21 
Exercise echocardiographic hemodynamics 




  Exercise mean PAP, mmHg 21±3 30±5 - 
  Exercise CO, l/min 6.4±2.4 5.4±1.6 <0.001 
  ΔTR-PG 7±4 16±7 <0.001 
  ΔmPAP 5±2 10±4 <0.001 
  ΔCO 2.4±1.9 1.6±0.8 <0.001 
ΔmPAP/ΔCO, mmHg/l/min 2.8±2.6 7.6±6.2 - 
Outcomes Hazard ratio 95% CI  
EIPH 1.95 1.10-3.45 0.023** 
Exercise right heart catheter group only Control Treatment  
Number 15 14  
Age 63±12 59±14 0.42 
Male, % 1 (7) 1 (7) 0.96 
History    
SS, % 13 (87) 10 (71) 0.33 
MCTD with SS features, % 2 (13) 4 (19) 0.33 
Medication    
PDE5 inhibitors, % 0 3 (22) - 
ERA, % 0 10 (71) - 
PGI2, % 0 1 (7) - 
Right heart catheter    
 mPAP at rest, mmHg 20±4 21±4 0.36 
 mPAP during exercise, mmHg 39±6 42±9 0.29 
 PAWP at rest, mmHg 9±3 10±3 0.49 
 PAWP during exercise, mmHg 16±3 17±3 0.43 
 CO at rest, l/min 6.0±1.7 4.8±1.1 0.03 
CO during exercise, l/min 9.7±2.6 8.4±2.3 0.16 
 PVR at rest, wood unit 1.9±0.8 2.6±1.1 0.07 
 PVR during exercise, wood unit 2.5±0.5 3.1±0.8 0.06 
Baseline    
 6MWD, meter 426±82 454±65 0.69* 
ΔmPAP/ΔCO, mmHg/l/min 5.7±2.7 6.8±2.9 0.30* 
At the 1 Year Follow-up    
  6MWD, meter 415±83 478±55 0.09* 
ΔmPAP/ΔCO, mmHg/l/min 6.8±3.2 4.4±2.7 0.02* 
Outcomes Hazard ratio 95% CI  
  Treatment 0.25 0.06-0.97 0.046† 
 
Data are presented as number of patients (percentage) and mean ± SD.  
Abbreviations: EIPH, exercise-induced pulmonary hypertension; WHO, world health 
organization; SS, scleroderma; MCTD, mixed connective tissue disease, %FEV1, percent forced 
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expiratory volume in 1 s; %FVC, percent forced vital capacity; %DLCO, diffusing capacity for 
carbon monoxide; HR, heart rate; BP, blood pressure; SpO2, percutaneous oxygen saturation, 
LVEDVi, left ventricular end-diastolic volume index; LVESVi, left ventricular end-systolic 
volume index; LVEF, left ventricular ejection fraction; LAVi, left atrial volume index; E, early 
diastolic transmitral flow velocity; e’, early diastolic mitral annular motion; RVEA, right 
ventricular end-diastolic area; RVESA, right ventricular end-systolic area; RVFAC, right 
ventricular functional area change; TAPSE, tricuspid annular plane systolic excursion; TR-PG, 
tricuspid regurgitant pressure gradient; mPAP, mean pulmonary artery pressure; CO, cardiac 
output; PDE5 inhibitors; phosphodiesterase type 5 inhibitors, ERA; endothelin receptor 
antagonists; PGI2, prostacyclin; PAWP, pulmonary artery wedge pressure; PVR, pulmonary 
vascular resistance; CI, confidence interval. 
*: p value on the basis of mixed effect model. 
**: p value on the basis of Cox proportional hazard model after adjustment of age, sex, and E/e’. 
†: p value on the basis of Cox proportional hazard model 
